MOONLAKE IMMUNOTHERAPEUTICS's ticker is and the CUSIP is 61559X104. A total of 25 filers reported holding MOONLAKE IMMUNOTHERAPEUTICS in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $119,135,472 | +15.6% | 2,090,096 | +3.4% | 0.02% | +19.0% |
| Q2 2023 | $103,051,008 | +64.8% | 2,020,608 | -30.9% | 0.02% | +50.0% |
| Q1 2023 | $62,532,339 | +106.4% | 2,923,438 | +1.3% | 0.01% | +100.0% |
| Q4 2022 | $30,303,967 | +41.7% | 2,886,092 | +7.5% | 0.01% | +40.0% |
| Q3 2022 | $21,380,000 | +53.6% | 2,685,937 | -0.6% | 0.01% | +25.0% |
| Q2 2022 | $13,916,000 | – | 2,702,661 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 21,751,284 | $1,109,315,484 | 30.92% |
| Cormorant Asset Management, LP | 8,142,100 | $415,247,100 | 23.26% |
| Ally Bridge Group (NY) LLC | 91,413 | $4,662,063 | 5.65% |
| Ghost Tree Capital, LLC | 330,000 | $16,830,000 | 5.56% |
| Finepoint Capital LP | 302,000 | $15,402,000 | 5.33% |
| 5AM Venture Management, LLC | 357,486 | $18,231,786 | 4.54% |
| Altium Capital Management LP | 88,000 | $4,488,000 | 3.40% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 200,000 | $10,200,000 | 3.16% |
| MPM BioImpact LLC | 295,111 | $15,050,661 | 3.03% |
| HighVista Strategies LLC | 129,722 | $6,615,822 | 3.03% |